Prot# MGL-3196-14: A 52-Week, Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients with Non-alcoholic Fatty Liver Disease (NAFLD) (MAESTRO-NAFLD-1)

Levitsky, Josh (PD/PI)

Medicine, Hepatology Division

Project: Research project

Status	Finished
Effective start/end date	7/28/20 → 10/31/23

Funding

Pharmaceutical Research Associates, Inc. (Prot# MGL-3196-14 // Prot# MGL-3196-14)
Synta Pharmaceuticals Corp. (Prot# MGL-3196-14 // Prot# MGL-3196-14)